What is AOA Dx?
AOA Dx is a pioneering life sciences enterprise dedicated to developing the first accurate, non-invasive diagnostic test for early-stage ovarian cancer. By leveraging advanced molecular diagnostics, the company aims to fundamentally improve clinical practice, reduce patient mortality rates, and provide substantial cost efficiencies for healthcare payers. Positioned at the intersection of oncology and diagnostic technology, AOA Dx is addressing a critical gap in women's health, moving beyond traditional screening limitations to offer a scalable, data-driven solution for early intervention.
How much funding has AOA Dx raised?
AOA Dx has raised a total of $24M across 2 funding rounds:
Angel/Seed
$7M
Other Financing Round
$17M
Angel/Seed (2022): $7M with participation from Joyance Partners, Avestria Ventures Management, Beacon Angels, AlleyCorp companies, RH Capital, SideCar Angels, TBD Angels, The Helm Management, Kyto Technology & Life Science, Pioneer Fund, and Launchpad Venture Group
Other Financing Round (2023): $17M led by Y Combinator, RH Capital, and Good Growth Capital
Key Investors in AOA Dx
Y Combinator
A premier startup accelerator and seed-stage venture firm that provides critical capital and mentorship to high-growth technology companies.
Good Growth Capital
An early-stage venture capital firm specializing in transformative science and technology, with a focus on life sciences and data-driven medical innovations.
Avestria Ventures Management
A specialized venture capital firm focused on early-stage women's health and life science companies that utilize technology to enhance healthcare quality.
What's next for AOA Dx?
With the infusion of recent capital, AOA Dx is well-positioned to transition from its developmental roots into a more mature commercialization phase. The company's strategic roadmap focuses on navigating complex regulatory landscapes and expanding its clinical evidence base to ensure widespread adoption. By prioritizing partnerships with healthcare providers and diagnostic networks, AOA Dx aims to solidify its market position as a leader in precision oncology, ultimately setting a new standard for ovarian cancer screening protocols globally.
See full AOA Dx company page
